Sweden’s access to rare-disease treatments is under debate.
A recent article on Lif’s news site highlights that, according to the 2025 WAIT report, only 22% of new non-oncology orphan medicines authorised by EMA were available to Swedish patients in 2025.
The article points to three areas that could improve access:
• Broader consideration of societal value in pricing and reimbursement assessments
• Faster and more predictable processes for introducing new treatments
• Better coordination between authorities, regions, healthcare providers and patients
It also highlights the importance of including patient and caregiver perspectives early in the process.
What does Sweden need to do differently to improve access to treatments for rare diseases?
Read the article on Lif: Fler med sällsynta diagnoser kan få behandling – vad vill Sverige?
#RareDiseases #PatientAccess #Healthcare #LifeScience
